Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trabectedin + Doxorubicin + Olaratumab in Leiomyosarcoma
NCT03437070Phase 1Withdrawn
- Sponsor
- University of Miami
- Start
- Jun 2019
- Primary completion
- Jun 2021
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
01
Overview
Phase 1, open-label trial of trabectedin in leiomyosarcoma (LMS), sponsored by University of Miami. Planned start Jun 2019; status: withdrawn.
02
Drugs
trabectedin
03
Conditions
leiomyosarcoma (LMS)
Beyond the preview
Go deeper on NCT03437070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03437070.